Outsourcing criteria within the Asia-Pacific

Outsourcing criteria within the Asia-Pacific

George Clinical (GC) conducted a brief survey on sponsors who are currently not a customer of GC.  30 companies were surveyed by GC’s Business Development Managers across six countries which included the United States, China, Australia, Korea, United Kingdom and Israel. The primary objective of the survey was to determine the services and countries that were important […]

Read More

September 3rd, 2015
George Clinical Staff Turnover

George Clinical Maintains Below Industry Average Staff Turnover

The cost of employee turnover in a Clinical Research Organisation (CRO) is high, as it weakens the relationship with the project sponsor. Research shows that in 2012, the CRO industry in the United States experienced a 12.5% voluntary turnover, compared to an average national voluntary turnover rate of 1.5%. During the 2015 financial year, George Clinical […]

Read More

September 3rd, 2015

China State Council’s new directive herald key changes for Chinese R&D

In a surprise move, the State Council in China has recently released a directive announcing its view on reforming the drug and medical device review and approval process in China. The State Council oversees the Chinese Food and Drug Administration (CFDA), and it is noteworthy that these changes were announced at a high level, reflecting […]

Read More

September 1st, 2015

George Clinical In China Celebrates Two Years As An Independent CRO

George Clinical in China recently celebrated its second anniversary as an independent entity in China. Although George Clinical has been conducting Phase 11 to Phase IV studies in China for over 8 years, previously it was incorporated into The George Institute in China – but now operates as a separate legal entity. The last two […]

Read More

August 26th, 2015

CFDA dramatically increase registration fees for drug and clinical trials

China is a highly attractive clinical trial destination, and continues to see increased interest from CROs and drug development companies. China has a well-established tradition of developing medicines from basic research and the demands for modern pharmaceuticals is growing. Data gathered from clinicaltrials.gov indicated that in 2014, China had conducted 846 clinical trials, and an […]

Read More

August 1st, 2015

George Clinical Supports Clinical Research Training in Asia

George Clinical (GC) is at the heart of developing Asia Clinical Research Professionals. This summer, our Clinical and Regulatory Manager, East Asia volunteered as a trainer for Asia Training Consortium (ATC) in its Foundational Clinical Project Management training program in Hong Kong. ATC is a non-profit organisation aimed at providing a unified platform for industry […]

Read More

July 13th, 2015

Therapeutic Goods Administration Releases New Online Form for Clinical Trial Notification (CTN) Scheme

The Therapeutic Goods Administration (TGA) has released a new online form for the clinical trial notification (CTN) scheme. When a clinical trial is investigating the use of a product within Australia, which is not on the Australian Register of Therapeutic Goods (ARTG), or on the ARTG yet being used outside its marketing approval conditions, these […]

Read More

July 7th, 2015
George Institue Logo

The George Institute’s Profile Featured in The Lancet

The George Institute was recently profiled in The Lancet; revered as one of the most prestigious, peer reviewed medical journals in the world. The Lancet Vol. 385 April 18, 2015 The feature article in The Lancet spoke of the Institute’s 16 year history from inception to the present time, where the George Institute is known […]

Read More

June 26th, 2015

Sulfagenix Inc. leverages the R&D Tax Incentive in Australia

Sulfagenix, Inc., a United States based biotech, was able to tap into Australia’s world class research and development (R&D) facilities and expertise

Read More

April 24th, 2015

Add George Clinical to your network